0000000000224767

AUTHOR

Eugen Rastorguev

showing 2 related works from this author

Use of Interferon-Alpha in Recurrent Respiratory Papillomatosis: 20-Year Follow-up

2005

Objectives: The aim of this study was analysis of the results of use of interferon-α (IFN-α) in patients with recurrent respiratory papillomatosis (RRP) and correlation of the results with human papillomavirus (HPV) type. Methods: A multicenter prospective series (42 patients from 22 hospitals) yielded 20 years of follow-up of patients with RRP and HPV typing who were treated with IFN-α in doses of 3 MU/m2 3 times per week. Results: During long-term follow-up (mean ± SD, 172 ± 36.8 months), the rate of event-free survival evaluated by Kaplan-Meier analysis was 42.8%, and the overall survival rate was 82.6%. The HPV typing revealed an association of HPV 11 with a more aggressive disease cour…

AdultMalemedicine.medical_specialtyAdolescentAlpha interferonAntineoplastic AgentsInjections IntramuscularDisease-Free Survival03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdjuvant therapyHumansDNA Probes HPVProspective StudiesHuman papillomavirusChild030223 otorhinolaryngologyProspective cohort studyLaryngeal NeoplasmsPapillomaviridaeInterferon alfaPapillomabusiness.industryIncidence (epidemiology)InfantInterferon-alphaGeneral MedicineMiddle AgedSurgeryClinical trialTreatment OutcomeOtorhinolaryngologyChild Preschool030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalRecurrent Respiratory PapillomatosisbusinessFollow-Up Studiesmedicine.drugAnnals of Otology, Rhinology & Laryngology
researchProduct

Incidence, age at onset, and potential reasons of malignant transformation in recurrent respiratory papillomatosis patients: 20 years experience

2005

Forty-two patients with recurrent respiratory papillomatosis (RRP) were accepted into a multicenter prospective study in 1983 to 1990, treated with alfa-IFN 3 MU/m 2 3 times a week and then followed-up until August 1, 2003. All the patients who had disease progression with pulmonary spread were characterized by insufficient response to IFN-therapy and detection of HPV type 11. Five patients (4/5 smokers) presented malignant transformation in lungs or nasopharynx (mean RRP duration was 27.2 +/- 8 years from RRP onset and 14.6 +/- 6.3 years from pulmonary spread until malignant transformation) with persistent RRP in larynx. The results of long-term follow-up in RRP patients with HPV 11 underl…

AdultMaleLarynxmedicine.medical_specialtyLung NeoplasmsTime FactorsAdolescentMalignant transformation03 medical and health sciences0302 clinical medicineInternal medicineHumansMedicineProspective StudiesTreatment FailureAge of Onset030223 otorhinolaryngologyProspective cohort studyPapillomaHpv typesbusiness.industryIncidenceIncidence (epidemiology)Disease progressionNasopharyngeal NeoplasmsSurgeryCell Transformation Neoplasticmedicine.anatomical_structureOtorhinolaryngologyChild Preschool030220 oncology & carcinogenesisFemaleSurgeryNeoplasm Recurrence LocalRecurrent Respiratory PapillomatosisAge of onsetbusinessFollow-Up StudiesOtolaryngology–Head and Neck Surgery
researchProduct